Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats

Hypertension Research

Volumn 33, Issue 3, 2010, Pages 229-235

  Sakurada, Maya ^a   Yoshimoto, Takanobu ^a   Sekizawa, Naoko ^a   Hirono, Yuki ^a   Suzuki, Noriko ^a   Hirata, Yukio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Cilostazol; Inflammation; NAD(P)H oxidase

Indexed keywords

ALDOSTERONE; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OSTEOPONTIN; P22PHOX PROTEIN; P47PHOX PROTEIN; PLATELET DERIVED GROWTH FACTOR A; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM PROTON EXCHANGE PROTEIN 1; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR INFLAMMATION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HEART WEIGHT; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ALDOSTERONE; ANIMALS; AORTA; ATHEROSCLEROSIS; BLOOD PRESSURE; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; HYPERTENSION; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; NITRIC OXIDE; OXIDATIVE STRESS; PHOSPHODIESTERASE INHIBITORS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-HYDROGEN ANTIPORTER; TETRAZOLES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 77749239888     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.211     Document Type: Article

References (54)

1. Funder JW. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 2004; 217: 263-269.
2. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J 2007; 54: 359-370.
3. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38: 1107-1111.
4. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M, Hirata Y. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 2007; 148: 1688-1696.
5. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens 2004; 17: 597-603.
6. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000; 101: 1722-1728.
7. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781.
8. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-1014.
9. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-171.
10. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteron-ism. Circulation 2004; 109: 2857-2861.
11. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003; 9: 2289-2302.
12. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A-and phosphatidylinositol 3-kinase/ Akt-dependent mechanism. Atherosclerosis 2006; 189: 350-357.
13. Morishita R. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl 2005; 6: 41-46.
14. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res 1997; 29: 491-495.
15. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004; 109: 1022-1028.
16. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 2005; 313: 502-509.
17. Takase H, Hashimoto A, Okutsu R, Hirose Y, Ito H, Imaizumi T, Miyakoda G, Mori T. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimit-telforschung 2007; 57: 185-191.
18. Akiyama H, Kudo S, Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arznei-mittelforschung 1985; 35: 1124-1132.
19. Kobayashi N, Nakano S, Mita S, Kobayashi T, Honda T, Tsubokou Y, Matsuoka H. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther 2002; 301: 459-466.
20. Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, Tateno T, Fukai N, Shichiri M, Hirata Y. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005; 146: 3900-3906.
21. Yoshimoto T, Gochou N, Fukai N, Sugiyama T, Shichiri M, Hirata Y. Adrenomedullin inhibits angiotensin II-induced oxidative stress and gene expression in rat endothelial cells. Hypertens Res 2005; 28: 165-172. (Pubitemid 40663068)
22. Tsuchiya K, Yoshimoto T, Hirono Y, Tateno T, Sugiyama T, Hirata Y. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006; 291: E771-E778.
23. Kawamura M, Miyazaki S, Teramoto T, Ashidate K, Thoda H, Ando N, Kaneko K. Gemfibrozil metabolite inhibits in vitro low-density lipoprotein (LDL) oxidation and diminishes cytotoxicity induced by oxidized LDL. Metabolism 2000; 49: 479-485.
24. Yoshimoto T, Naruse M, Irie K, Tanabe A, Seki T, Tanaka M, Imaki T, Naruse K, Muraki T, Matsuda Y, Demura H. Beta-adrenoceptor antagonist propranolol potentiates hypo-tensive action of natriuretic peptides. Eur J Pharmacol 1998; 351: 61-66.
25. Karmazyn M, Liu Q, Gan XT, Brix BJ, Fliegel L. Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes. Hypertension 2003; 42: 1171-1176. (Pubitemid 37549073)
26. Verrey F, Loffing J, Zecevic M, Heitzmann D, Staub O. SGK1: aldosterone-induced relay of Na+ transport regulation in distal kidney nephron cells. Cell Physiol Biochem 2003; 13: 21-28.
27. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-933.
28. Schulz E, Jansen T, Wenzel P, Daiber A, Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008; 10: 1115-1126.
29. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002; 970: 89-100.
30. Weber KT. Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone. J Lab Clin Med 2003; 142: 71-82.
31. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, Kasayama S. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Atherosclerosis 2001; 158: 121-128.
32. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005; 28: 925-936.
33. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA, Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.
34. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004; 15: 237-254.
35. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359.
36. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2302-2309.
37. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, Minami I, Iwashima F, Sakai H, Tateno T, Sato R, Hirata Y. Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 2005; 336: 163-167.
38. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-848.
39. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R277-R297.
40. Koike N, Takamura T, Kaneko S. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor. Life Sci 2007; 80: 1721-1728.
41. Akram S, Teong HF, Fliegel L, Pervaiz S, Clement MV. Reactive oxygen species-mediated regulation of the Na+-H+ exchanger 1 gene expression connects intracellular redox status with cells' sensitivity to death triggers. Cell Death Differ 2006; 13: 628-641.
42. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364.
43. Dalainas I. Cilostazol in the management of vascular disease. Int Angiol 2007; 26: 1-7.
44. Shah DI, Singh M. Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats. Fundam Clin Pharmacol 2006; 20: 595-604.
45. Liu J, Shimosawa T, Matsui H, Meng F, Supowit SC, DiPette DJ, Ando K, Fujita T. Adrenomedullin inhibits angiotensin II-induced oxidative stress via Csk-mediated inhibition of Src activity. Am J Physiol Heart Circ Physiol 2007; 292: H1714-H1721.
46. Yoshimoto T, Fukai N, Sato R, Sugiyama T, Ozawa N, Shichiri M, Hirata Y. Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells. Endocrinology 2004; 145: 3331-3337.
47. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801-1802.
48. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldoster-onism. Hypertension 1996; 27: 1039-1045.
49. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995; 18: 370-373.
50. Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R. Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorti-costerone acetate induced hypertension in rats. J Hypertens 2000; 18: 919-926.
51. Umegaki K, Nakamura K, Ikeda M, Inoue Y, Tomita T. Changes in platelet function due to hypertension: comparison of experimental hypertension with spontaneous hypertension in rats. J Hypertens 1989; 7: 13-19.
52. Umegaki K, Saegusa H, Kurokawa M, Ichikawa T. Effects of vitamin E administration on platelet function and serum lipid peroxides in DOCA-salt hypertensive rats. Thromb Haemost 1991; 65: 411-414.
53. Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol 2003; 23: 1345-1351.
54. Ishizuka T, Niwa A, Tabuchi M, Ooshima K, Higashino H. Acetylsalicylic acid provides cerebrovascular protection from oxidant damage in salt-loaded stroke-prone rats. Life Sci 2008; 82: 806-815.